These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36609991)

  • 1. Molecular characteristics of low-grade serous carcinoma in effusions.
    Doutel D; Davidson B; Nitschke Pettersen IK; Torgunrud A
    Cytopathology; 2023 Mar; 34(2):99-105. PubMed ID: 36609991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
    Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
    J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
    Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
    Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
    Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
    J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
    Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
    Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
    Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
    Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum of
    Chui MH; Chang JC; Zhang Y; Zehir A; Schram AM; Konner J; Drilon AE; Da Cruz Paula A; Weigelt B; Grisham RN
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34568720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.
    Murali R; Selenica P; Brown DN; Cheetham RK; Chandramohan R; Claros NL; Bouvier N; Cheng DT; Soslow RA; Weigelt B; McCluggage WG
    Histopathology; 2019 Mar; 74(4):638-650. PubMed ID: 30565721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.
    Manning-Geist B; Gordhandas S; Liu YL; Zhou Q; Iasonos A; Da Cruz Paula A; Mandelker D; Long Roche K; Zivanovic O; Maio A; Kemel Y; Chi DS; O'Cearbhaill RE; Aghajanian C; Weigelt B; Chui MH; Grisham RN
    Clin Cancer Res; 2022 Oct; 28(20):4456-4465. PubMed ID: 35443055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-grade serous carcinoma detected from intraoperative peritoneal washings: Cytological findings and detection of KRAS mutation.
    Yamamoto E; Warigaya K; Kinoshita Y; Yamamoto A; Murata SI
    Cancer Rep (Hoboken); 2022 Oct; 5(10):e1676. PubMed ID: 35801373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
    Zhang X; Devins K; Ko EM; Reyes MC; Simpkins F; Drapkin R; Schwartz LE; Yoon JY
    Gynecol Oncol; 2021 Jun; 161(3):762-768. PubMed ID: 33773808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
    Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
    J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Frequency of
    Ishibashi T; Nakayama K; Razia S; Ishikawa M; Nakamura K; Yamashita H; Dey P; Iida K; Kurioka H; Nakayama S; Otsuki Y; Ishikawa N; Kyo S
    Diagnostics (Basel); 2019 Dec; 10(1):. PubMed ID: 31892193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
    Qiu C; Lu N; Wang X; Zhang Q; Yuan C; Yan S; Dongol S; Li Y; Sun X; Sun C; Zhang Z; Zheng W; Kong B
    Gynecol Oncol; 2017 Dec; 147(3):634-641. PubMed ID: 28965696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the tumour microenvironment mark the transition from serous borderline tumour to low-grade serous carcinoma.
    Vallejos R; Zhantuyakova A; Negri GL; Martin SD; Spencer SE; Thornton S; Leung S; Lynch B; Qin Y; Chow C; Liang B; Zdravko S; Douglas JM; Milne K; Mateyko B; Nelson BH; Howitt BE; Kommoss FK; Horn LC; Hoang L; Singh N; Morin GB; Huntsman DG; Cochrane D
    J Pathol; 2024 Oct; 264(2):197-211. PubMed ID: 39081243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations.
    Davidson B; Holth A; Lindemann K; Zahl Eriksson AG; Nilsen TA; Torgunrud A
    Virchows Arch; 2024 May; ():. PubMed ID: 38733380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal Proliferations in Completely Examined Fallopian Tubes Accompanying Ovarian Low-grade Serous Tumors: Neoplastic Precursor Lesions or Normal Variants of Benign Mucosa?
    Wolsky RJ; Price MA; Zaloudek CJ; Rabban JT
    Int J Gynecol Pathol; 2018 May; 37(3):262-274. PubMed ID: 28700429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian Combined Serous Borderline Tumor/Low-grade Serous Carcinoma and Mesonephric-like Lesion: Report of 2 Cases With New Observations.
    Nilforoushan N; Liu L; Finkelman BS; Andersen J; Liu Y; James J; Hung CF; Wu TC; Vang R; Xing D
    Int J Gynecol Pathol; 2023 Mar; 42(2):182-191. PubMed ID: 35348533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.